Cargando…

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres

BACKGROUND: Treatment options for patients with metastatic colorectal cancer (mCRC) include anti-epithelial growth factor therapies, which, in Europe, are indicated in patients with RAS wild-type tumours only and require prior mutation testing of “hot-spot” codons in exons 2, 3 and 4 of KRAS and NRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boleij, Annemarie, Tack, Véronique, Taylor, Aliki, Kafatos, George, Jenkins-Anderson, Sophie, Tembuyser, Lien, Dequeker, Els, van Krieken, J. Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080758/ https://www.ncbi.nlm.nih.gov/pubmed/27784278 http://dx.doi.org/10.1186/s12885-016-2810-3

Ejemplares similares

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers
por: Boleij, Annemarie, et al.
Publicado: (2015)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review
por: Han van Krieken, J., et al.
Publicado: (2017)

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data
por: Kafatos, George, et al.
Publicado: (2017)

The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling
por: Cui, Yan, et al.
Publicado: (2019)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Ras protein abundance correlates with Ras isoform mutation patterns in cancer
por: Hood, Fiona E., et al.
Publicado: (2023)

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization
por: Tembuyser, Lien, et al.
Publicado: (2014)

Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review
por: Trojan, Jörg, et al.
Publicado: (2015)

Dynamic regulation of RAS and RAS signaling
por: Kolch, Walter, et al.
Publicado: (2023)

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer
por: Isnaldi, Edoardo, et al.
Publicado: (2019)

Ras p21 in breast tissue: associations with pathology and cellular localisation.
por: Going, J. J., et al.
Publicado: (1992)

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
por: Keppens, Cleo, et al.
Publicado: (2018)

Lipid Profiles of RAS Nanoclusters Regulate RAS Function
por: Zhou, Yong, et al.
Publicado: (2021)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Ras on the inside
por: LeBrasseur, Nicole
Publicado: (2002)

Escorting Ras
por: Zheng, Ze-Yi, et al.
Publicado: (2012)

Local RAS
por: Leung, Po Sing
Publicado: (2010)

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally
por: Miller, Mark Steven, et al.
Publicado: (2012)

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
por: Abankwa, Daniel, et al.
Publicado: (2020)

RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
por: Peeters, Marc, et al.
Publicado: (2015)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications
por: Ferro, Elisa, et al.
Publicado: (2012)

Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies
por: Ramos-Kuri, Manuel, et al.
Publicado: (2021)

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes
por: Stephens, Robert M, et al.
Publicado: (2017)

Killer K-Ras
por: Powell, Kendall
Publicado: (2006)

Ras in epidermal proliferation
por: Drosten, Matthias, et al.
Publicado: (2014)

RAS variant signalling
por: Mo, Stephanie P., et al.
Publicado: (2018)

SUMO wrestling with Ras
por: Zhang, Haibo, et al.
Publicado: (2016)

The Ras dimer structure
por: Rudack, Till, et al.
Publicado: (2021)

K-RAS Is…Complicated
por: Clark, Geoffrey J.
Publicado: (2023)

The Distinct Conformational Dynamics of K-Ras and H-Ras A59G
por: Lukman, Suryani, et al.
Publicado: (2010)

Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1
por: Iwig, Jeffrey S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dkohltog9r5vj20216bin8fvb0